{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:41:21Z","timestamp":1761864081200,"version":"3.37.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11033-020-05269-x","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T23:02:33Z","timestamp":1580857353000},"page":"2361-2369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting gallbladder cancer: a pathway based perspective"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-9999","authenticated-orcid":false,"given":"P.","family":"Baichan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. S.","family":"Devar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. P.","family":"Candy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nweke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"5269_CR1","unstructured":"DeStoll M (1777) Rationis medendi in practice Unindobonensi. Part Bernard Vienna"},{"key":"5269_CR2","unstructured":"DeStoll M (1788) Rationis mendendi. Nosocomio Pract Vendobonensi Part 1"},{"issue":"6","key":"5269_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: Global Cancer Statistics 2018. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"5269_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U","volume":"70","author":"DE Henson","year":"1992","unstructured":"Henson DE, Albores-Saavedra J, Code D (1992) Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 70:1493\u20131497","journal-title":"Cancer"},{"key":"5269_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.2147\/OTT.S46897","volume":"6","author":"P Leal","year":"2013","unstructured":"Leal P, Garcia P, Sandoval A et al (2013) AKT\/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. OncoTargets Ther 6:1373. https:\/\/doi.org\/10.2147\/OTT.S46897","journal-title":"OncoTargets Ther"},{"key":"5269_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","volume":"51","author":"EC Lazcano-Ponce","year":"2001","unstructured":"Lazcano-Ponce EC, Miquel JF, Munoz N et al (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51:349\u2013364. https:\/\/doi.org\/10.3322\/canjclin.51.6.349","journal-title":"CA Cancer J Clin"},{"key":"5269_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0304-3835(01)00562-6","volume":"169","author":"Y-T Kim","year":"2001","unstructured":"Kim Y-T, Kim J, Jang YH et al (2001) Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 169:59\u201368. https:\/\/doi.org\/10.1016\/S0304-3835(01)00562-6","journal-title":"Cancer Lett"},{"issue":"6","key":"5269_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","volume":"68","author":"M Li","year":"2018","unstructured":"Li M, Liu F, Zhang F et al (2018) Genomic ERBB2 \/ ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut 68(6):1024\u20131033. https:\/\/doi.org\/10.1136\/gutjnl-2018-316039","journal-title":"Gut"},{"key":"5269_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2%3c267::AID-CNCR10%3e3.0.CO;2-R","volume":"83","author":"S Tanno","year":"1998","unstructured":"Tanno S, Obara T, Fujii T et al (1998) Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 83:267\u2013275. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19980715)83:2%3c267:AID-CNCR10%3e3.0.CO;2-R","journal-title":"Cancer"},{"key":"5269_CR10","first-page":"2511","volume":"55","author":"II Wistuba","year":"1995","unstructured":"Wistuba II, Sugio K, Hung J et al (1995) Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 55:2511\u20132515","journal-title":"Cancer Res"},{"key":"5269_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3%3c452::AID-CNCR5%3e3.0.CO;2-M","volume":"77","author":"K Hanada","year":"1996","unstructured":"Hanada K, Itoh M, Fujii K et al (1996) K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer Interdiscip Int J Am Cancer Soc 77:452\u2013458. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19960201)77:3%3c452:AID-CNCR5%3e3.0.CO;2-M","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"key":"5269_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11605-006-0075-x","volume":"11","author":"KM Reid","year":"2007","unstructured":"Reid KM, Ramos-De la Medina A, Donohue JH (2007) Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 11:671\u2013681. https:\/\/doi.org\/10.1007\/s11605-006-0075-x","journal-title":"J Gastrointest Surg"},{"key":"5269_CR13","first-page":"297","volume":"7","author":"N Yokoyama","year":"1998","unstructured":"Yokoyama N, Hitomi J, Watanabe H et al (1998) Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Prev Biomark 7:297\u2013301","journal-title":"Cancer Epidemiol Prev Biomark"},{"key":"5269_CR14","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA (2014) Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 6:99","journal-title":"Clin Epidemiol"},{"key":"5269_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.12659\/PJR.893705","volume":"80","author":"A Monier","year":"2015","unstructured":"Monier A, Saloum N, Szmigielski W et al (2015) Neuroendocrine tumor of the gallbladder. Pol J Radiol 80:228\u2013231. https:\/\/doi.org\/10.12659\/PJR.893705","journal-title":"Pol J Radiol"},{"key":"5269_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/jcp.47.5.453","volume":"47","author":"A Wee","year":"1994","unstructured":"Wee A, Teh M, Raju GC (1994) Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol 47:453\u2013456. https:\/\/doi.org\/10.1136\/jcp.47.5.453","journal-title":"J Clin Pathol"},{"key":"5269_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0027-5107(00)00022-1","volume":"450","author":"GP Pfeifer","year":"2000","unstructured":"Pfeifer GP (2000) p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 450:155\u2013166","journal-title":"Mutat Res"},{"key":"5269_CR18","first-page":"461","volume":"5","author":"K Fujii","year":"1996","unstructured":"Fujii K, Yokozaki H, Yasui W et al (1996) High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. Cancer Epidemiol Prev Biomark 5:461\u2013466","journal-title":"Cancer Epidemiol Prev Biomark"},{"key":"5269_CR19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.1174229","volume":"325","author":"J Yun","year":"2009","unstructured":"Yun J, Rago C, Cheong I et al (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325:1555\u20131559. https:\/\/doi.org\/10.1126\/science.1174229","journal-title":"Science"},{"key":"5269_CR20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/modpathol.2011.109","volume":"24","author":"SI Chiosea","year":"2011","unstructured":"Chiosea SI, Sherer CK, Jelic T, Dacic S (2011) KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol 24:1571\u20131577. https:\/\/doi.org\/10.1038\/modpathol.2011.109","journal-title":"Mod Pathol"},{"key":"5269_CR21","first-page":"1457","volume":"44","author":"T Iwase","year":"1997","unstructured":"Iwase T, Nakazawa S, Yamao K et al (1997) Ras gene point mutations in gallbladder lesions associated with anomalous connection of pancreatobiliary ducts. Hepatogastroenterology 44:1457\u20131462","journal-title":"Hepatogastroenterology"},{"key":"5269_CR22","first-page":"1127","volume":"8","author":"YW Kim","year":"2001","unstructured":"Kim YW, Huh SH, Park YK et al (2001) Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 8:1127\u20131132","journal-title":"Oncol Rep"},{"key":"5269_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"RJ Roskoski","year":"2014","unstructured":"Roskoski RJ (2014) The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34\u201374","journal-title":"Pharmacol Res"},{"key":"5269_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MPH.0000000000000329","volume":"37","author":"D King","year":"2015","unstructured":"King D, Yeomanson D, Bryant HE (2015) PI3King the Lock: Targeting the PI3K\/Akt\/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol 37:245\u2013251","journal-title":"J Pediatr Hematol Oncol"},{"key":"5269_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S1072-7515(01)01012-2","volume":"193","author":"ZW Quan","year":"2001","unstructured":"Quan ZW, Wu K, Wang J et al (2001) Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 193:380\u2013383. https:\/\/doi.org\/10.1016\/S1072-7515(01)01012-2","journal-title":"J Am Coll Surg"},{"key":"5269_CR26","first-page":"318","volume":"85","author":"T Mikami","year":"1999","unstructured":"Mikami T, Yanagisawa N, Baba H et al (1999) Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer Interdiscip Int J Am Cancer Soc 85:318\u2013325","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"key":"5269_CR27","first-page":"1157","volume":"8","author":"T Asano","year":"2002","unstructured":"Asano T, Shoda J, Ueda T et al (2002) Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8:1157\u20131167","journal-title":"Clin Cancer Res"},{"key":"5269_CR28","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.3748\/wjg.v11.i24.3724","volume":"11","author":"YH Zhi","year":"2005","unstructured":"Zhi YH, Liu RS, Song MM et al (2005) Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 11:3724. https:\/\/doi.org\/10.3748\/wjg.v11.i24.3724","journal-title":"World J Gastroenterol"},{"key":"5269_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.prp.2017.01.025","volume":"213","author":"K Buchegger","year":"2017","unstructured":"Buchegger K, Silva R, L\u00f3pez J et al (2017) The ERK\/MAPK pathway is overexpressed and activated in gallbladder cancer. Pathol Res Pract 213:476\u2013482. https:\/\/doi.org\/10.1016\/j.prp.2017.01.025","journal-title":"Pathol Res Pract"},{"key":"5269_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ctrv.2015.01.003","volume":"41","author":"C Bizama","year":"2015","unstructured":"Bizama C, Garc\u00eda P, Espinoza JA et al (2015) Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev 41:222\u2013234. https:\/\/doi.org\/10.1016\/j.ctrv.2015.01.003","journal-title":"Cancer Treat Rev"},{"key":"5269_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ctrv.2014.02.003","volume":"40","author":"J Brechbiel","year":"2014","unstructured":"Brechbiel J, Miller-Moslin K, Adjei AA (2014) Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev 40:750\u2013759. https:\/\/doi.org\/10.1016\/j.ctrv.2014.02.003","journal-title":"Cancer Treat Rev"},{"key":"5269_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0746-9","author":"P Du","year":"2019","unstructured":"Du P, Liang H, Fu X et al (2019) SLC25A22 promotes proliferation and metastasis by activating MAPK\/ERK pathway in gallbladder cancer. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-019-0746-9","journal-title":"Cancer Cell Int"},{"key":"5269_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4161\/cbt.28584","volume":"15","author":"X-S Wu","year":"2014","unstructured":"Wu X-S, Wang X-A, Wu W-G et al (2014) MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK\/MAPK pathway. Cancer Biol Ther 15:806\u2013814. https:\/\/doi.org\/10.4161\/cbt.28584","journal-title":"Cancer Biol Ther"},{"key":"5269_CR34","first-page":"7","volume":"7","author":"I Roa","year":"2014","unstructured":"Roa I, de Toro G, Schalper K et al (2014) Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res 7:7","journal-title":"Gastrointest Cancer Res"},{"key":"5269_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","volume":"8","author":"M Javle","year":"2015","unstructured":"Javle M, Churi C, Kang HC et al (2015) HER2\/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8:58. https:\/\/doi.org\/10.1186\/s13045-015-0155-z","journal-title":"J Hematol Oncol"},{"key":"5269_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5858\/arpa.2012-0032-OA","volume":"137","author":"P Leal","year":"2013","unstructured":"Leal P, Garc\u00eda P, Sandoval A et al (2013) Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med 137:552\u2013557. https:\/\/doi.org\/10.5858\/arpa.2012-0032-OA","journal-title":"Arch Pathol Lab Med"},{"key":"5269_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.18632\/oncotarget.1808","volume":"5","author":"A Lunardi","year":"2014","unstructured":"Lunardi A, Webster KA, Papa A et al (2014) Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget 5:894\u2013900. https:\/\/doi.org\/10.18632\/oncotarget.1808","journal-title":"Oncotarget"},{"key":"5269_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-014-0276-y","volume":"14","author":"Y-J Shu","year":"2015","unstructured":"Shu Y-J, Weng H, Ye Y-Y et al (2015) SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K\/AKT pathway. Mol Cancer 14:12. https:\/\/doi.org\/10.1186\/s12943-014-0276-y","journal-title":"Mol Cancer"},{"key":"5269_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2015.01.041","volume":"360","author":"Y Cao","year":"2015","unstructured":"Cao Y, Liu X, Lu W et al (2015) Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer. Cancer Lett 360:141\u2013150. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.041","journal-title":"Cancer Lett"},{"key":"5269_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/hep.510230305","volume":"23","author":"T K\u00f6rner","year":"1996","unstructured":"K\u00f6rner T, Kropf J, Hackler R et al (1996) Fibronectin in human bile fluid for diagnosis of malignant biliary diseases: fibronectin in human bile fluid for diagnosis of malignant biliary diseases. Hepatology 23:423\u2013428. https:\/\/doi.org\/10.1002\/hep.510230305","journal-title":"Hepatology"},{"key":"5269_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/cas.12073","volume":"104","author":"H Iwasaki","year":"2013","unstructured":"Iwasaki H, Nakano K, Shinkai K et al (2013) Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via upregulation of adherence-related genes. Cancer Sci 104:328\u2013336","journal-title":"Cancer Sci"},{"key":"5269_CR42","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/0008-5472.CAN-04-0416","volume":"64","author":"M Kubo","year":"2004","unstructured":"Kubo M, Nakamura M, Tasaki A et al (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64:6071\u20136074. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0416","journal-title":"Cancer Res"},{"key":"5269_CR43","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1349-7006.2011.01912.x","volume":"102","author":"H Onishi","year":"2011","unstructured":"Onishi H, Kai M, Odate S et al (2011) Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 102:1144\u20131150","journal-title":"Cancer Sci"},{"key":"5269_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jso.20606","volume":"95","author":"K Yanai","year":"2007","unstructured":"Yanai K, Nagai S, Wada J et al (2007) Hedgehog signaling pathway is a possible therapeutic target for gastric cancer. J Surg Oncol 95:55\u201362","journal-title":"J Surg Oncol"},{"key":"5269_CR45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/cas.12354","volume":"105","author":"S Matsushita","year":"2014","unstructured":"Matsushita S, Onishi H, Nakano K et al (2014) Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer. Cancer Sci 105:272\u2013280. https:\/\/doi.org\/10.1111\/cas.12354","journal-title":"Cancer Sci"},{"key":"5269_CR46","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s00595-012-0157-1","volume":"42","author":"J Li","year":"2012","unstructured":"Li J, Wu T, Lu J et al (2012) Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma. Surg Today 42:770\u2013775. https:\/\/doi.org\/10.1007\/s00595-012-0157-1","journal-title":"Surg Today"},{"key":"5269_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.humpath.2013.10.017","volume":"45","author":"F Xie","year":"2014","unstructured":"Xie F, Xu X, Xu A et al (2014) Aberrant activation of Sonic hedgehog signaling in chronic cholecystitis and gallbladder carcinoma. Hum Pathol 45:513\u2013521. https:\/\/doi.org\/10.1016\/j.humpath.2013.10.017","journal-title":"Hum Pathol"},{"key":"5269_CR48","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1021\/bi00379a035","volume":"26","author":"Y Yarden","year":"1987","unstructured":"Yarden Y, Schlessinger J (1987) Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26:1443\u20131451. https:\/\/doi.org\/10.1021\/bi00379a035","journal-title":"Biochemistry"},{"key":"5269_CR49","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"5269_CR50","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2407-10-631","volume":"10","author":"Y Pignochino","year":"2010","unstructured":"Pignochino Y, Sarotto I, Peraldo-Neia C et al (2010) Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631. https:\/\/doi.org\/10.1186\/1471-2407-10-631","journal-title":"BMC Cancer"},{"key":"5269_CR51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10616-014-9763-7","volume":"68","author":"Y Liu","year":"2016","unstructured":"Liu Y, Bi T, Shen G et al (2016) Lupeol induces apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD cells by suppression of EGFR\/MMP-9 signaling pathway. Cytotechnology 68:123\u2013133. https:\/\/doi.org\/10.1007\/s10616-014-9763-7","journal-title":"Cytotechnology"},{"key":"5269_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-016-0370-7","volume":"35","author":"S Zhao","year":"2016","unstructured":"Zhao S, Cao Y, Liu S et al (2016) The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. J Exp Clin Cancer Res 35:97. https:\/\/doi.org\/10.1186\/s13046-016-0370-7","journal-title":"J Exp Clin Cancer Res"},{"key":"5269_CR53","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/jcb.20678","volume":"97","author":"H Ariyama","year":"2006","unstructured":"Ariyama H, Qin B, Baba E et al (2006) Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97:724\u2013734. https:\/\/doi.org\/10.1002\/jcb.20678","journal-title":"J Cell Biochem"},{"key":"5269_CR54","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3748\/wjg.v17.i35.4023","volume":"17","author":"HA Yoon","year":"2011","unstructured":"Yoon HA, Noh MH, Kim BG et al (2011) Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 17:4023\u20134030. https:\/\/doi.org\/10.3748\/wjg.v17.i35.4023","journal-title":"World J Gastroenterol"},{"key":"5269_CR55","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12253-015-0019-4","volume":"22","author":"L Liu","year":"2016","unstructured":"Liu L, Yang Z, Wang C et al (2016) The Expression of Notch 1 and Notch 3 in gallbladder cancer and their clinicopathological significance. Pathol Oncol Res 22:483\u2013492. https:\/\/doi.org\/10.1007\/s12253-015-0019-4","journal-title":"Pathol Oncol Res"},{"key":"5269_CR56","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW et al (1991) Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110\u20136117","journal-title":"Cancer Res"},{"key":"5269_CR57","doi-asserted-by":"publisher","first-page":"16856","DOI":"10.1073\/pnas.1304355110","volume":"110","author":"F K\u00f6pper","year":"2013","unstructured":"K\u00f6pper F, Bierwirth C, Schon M et al (2013) Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci 110:16856\u201316861. https:\/\/doi.org\/10.1073\/pnas.1304355110","journal-title":"Proc Natl Acad Sci"},{"key":"5269_CR58","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1093\/nar\/21.25.5846","volume":"21","author":"D Payet","year":"1993","unstructured":"Payet D, Gaucheron F, Sip M, Leng M (1993) Instability of the monofunctional adducts in cis -[Pt(NH 3) 2 ( N7-N -methyl-2-diazapyrenium)CI] 2+;-modified DNA: rates of cross-linking reactions in cis -platinummodified DNA. Nucleic Acids Res 21:5846\u20135851. https:\/\/doi.org\/10.1093\/nar\/21.25.5846","journal-title":"Nucleic Acids Res"},{"key":"5269_CR59","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.1997.15.7.2691","volume":"15","author":"MJ McKeage","year":"1997","unstructured":"McKeage MJ, Raynaud F, Ward J et al (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691\u20132700","journal-title":"J Clin Oncol"},{"key":"5269_CR60","doi-asserted-by":"publisher","first-page":"996","DOI":"10.21037\/jgo.2016.09.10","volume":"7","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Sendilnathan A, Siddiqi NI et al (2016) Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol 7:996\u20131003. https:\/\/doi.org\/10.21037\/jgo.2016.09.10","journal-title":"J Gastrointest Oncol"},{"key":"5269_CR61","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/0284186X.2017.1418532","volume":"57","author":"J Dierks","year":"2018","unstructured":"Dierks J, Gaspersz MP, Belkouz A et al (2018) Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol 57:807\u2013812. https:\/\/doi.org\/10.1080\/0284186X.2017.1418532","journal-title":"Acta Oncol"},{"key":"5269_CR62","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus Gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"5269_CR63","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330\u2013338. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"5269_CR64","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332\u20132338. https:\/\/doi.org\/10.1200\/JCO.2005.51.008","journal-title":"J Clin Oncol"},{"key":"5269_CR65","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/cncr.22902","volume":"110","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Townsley CA, Chin SN et al (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307\u20131312. https:\/\/doi.org\/10.1002\/cncr.22902","journal-title":"Cancer"},{"key":"5269_CR66","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.2147\/DDDT.S84527","volume":"9","author":"F Zhang","year":"2015","unstructured":"Zhang F, Wu X, Hu Y et al (2015) 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des Devel Ther 9:3969. https:\/\/doi.org\/10.2147\/DDDT.S84527","journal-title":"Drug Des Devel Ther"},{"key":"5269_CR67","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1471-2407-14-217","volume":"14","author":"R Bao","year":"2014","unstructured":"Bao R, Shu Y, Wu X et al (2014) Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer 14:217. https:\/\/doi.org\/10.1186\/1471-2407-14-217","journal-title":"BMC Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-05269-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-020-05269-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-05269-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:54:12Z","timestamp":1612313652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-020-05269-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["5269"],"URL":"https:\/\/doi.org\/10.1007\/s11033-020-05269-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"10 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}